title: Antibacterial bioagents based on principles of bacteriophage biology: an overview.
abstract: Bacteriophages were discovered almost a century ago. With the advent of antibiotics, the use of bacteriophages for treatment of infections fell out of favor in Western medicine. In light of the rise of antibiotic resistance, phages and their products (lysins) are rediscovered as antibacterial bioagents. This overview summarizes principles of phage biology and their translation for therapeutic and preventive applications. Examples are presented to highlight their therapeutic promise for prophylaxis and treatment of bacterial infections including multidrug-resistant organisms in humans and animals, and their use as decontaminants of food supplies and environments. Besides research on the in vivo behavior of phages and lysins, dialogues between researchers and regulatory agencies are necessary to publish guidelines for bacteriophage manufacturing and formulation for human use. Only well-designed, double-blind randomized controlled trials will determine if phages and lysins are safe and effective adjuncts or alternatives to antibiotic therapy for infections with multidrug-resistant organisms.
authors.affiliation: Department of Medicine, Infectious Diseases Division, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island.
authors.forename: Bettina M
authors.initials: BM
authors.lastname: Knoll
authors.forename: Eleftherios
authors.initials: E
authors.lastname: Mylonakis
mesh_terms: D000818:Animals; D001419:Bacteria / Q000821:virology*; D001424:Bacterial Infections / Q000517:prevention & control / Q000628:therapy* / Q000662:veterinary*; D001435:Bacteriophages / Q000254:growth & development*; D001691:Biological Therapy / Q000009:adverse effects / Q000379:methods*; D002986:Clinical Trials as Topic; D010450:Endopeptidases / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans
chemical_list: D010450:Endopeptidases; C001143:endolysin
keywords: bacteriophages; lysins; multidrug-resistant bacteria